News
Epocal Announces FDA Clearance of Lactate Test
Test further expands clinical utility of
epoc®
System for point-of-care blood analysis
Press Release
Ottawa, Ontario
June 14, 2010
OTTAWA, ON Canada – Jun. 14, 2010 -- Epocal, Inc., a leading edge provider
of point of care technology, announced today that it has received U.S. Food
and Drug Administration (FDA) clearance to market its new lactate test on
the
epoc
Blood Analysis System. Lactate measurements from the
epoc
System are used to evaluate acid-base status and for diagnosis and treatment
of lactic acidosis (abnormally high acidity of the blood).
The addition of lactate to the
epoc
BGEM Test Card, which includes in vitro diagnostic tests for pH, pO2, pCO2,
Na, K, iCa, Hct and Glu (plus calculated values), further expands the
clinical utility of the Company's point of care blood gas and electrolyte
platform. Lactate on the BGEM
Test Card represents the second metabolite cleared for use on the
epoc
System in the past 12 months.
It is also the ninth measured analyte on the single-use test card,
surpassing most competitive point of care systems which may require multiple
test devices in order to match the same menu.
“Epocal reaffirms its commitment to patient care by adding this critical
test to its cost effective, comprehensive point of care platform.” said
Imants Lauks, Epocal Inventor and CEO.
“The epoc technology continues to excite healthcare with its ability
to improve delivery of patient care, reduce operating expenses and increase
efficiency throughout the entire healthcare enterprise."
About Epocal, Inc.
Epocal, Inc., headquartered in
critical caregivers with real-time, laboratory quality test results at the
patient's bedside.
The
epoc
System is marketed co-exclusively by Epocal, Inc. and Alere in all
geographies worldwide, except for